FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused…
ROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage…
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing…
Topline results from CATT1 Phase 3 trial expected in second half of 2026HIGH POINT, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE)…
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a…
The final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD…
MONTREAL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nualtis (formerly IntelGenx Corp.), a leader in oral film drug delivery technologies, today…
Topline results for the Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism on track for Q3 2025 Imapextide (MBX 1416)…
The Group's advanced technologies and made in Italy quality ensure compliance to global standards, supply chain integrity and patient safety…
Where Is the DEA? The Real Threat Isn't Research-It's Rotten Weed."This is the height of hypocrisy," said Duane Boise, CEO…